Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.38 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL27520052 | 0.98 | ESR2 (0.57) | ESR2ALDH1A1MAPK1CYP2A6CYP2B6 | |
| Acetic Acid SCHEMBL11702188 | 0.91 | ALDH1A1 (0.55) | ESR2ALDH1A1PTGDR2PPARGPPARA | |
| SCHEMBL30414134 | 0.86 | ESR2 (0.42) | ESR2ALDH1A1MAPK1CYP2A6 | |
| SCHEMBL679627 | 0.86 | ESR2 (0.42) | ESR2ALDH1A1MAPK1CYP2A6 | |
| SCHEMBL25056756 | 0.86 | ALDH1A1 (0.58) | ESR2ALDH1A1MAPK1CYP2A6CYP2B6 | |
| SCHEMBL17574346 | 0.86 | ALDH1A1 (0.52) | ESR2ALDH1A1MAPK1PTPRCALOX5 | |
| SCHEMBL6519997 | 0.84 | ALDH1A1 (0.42) | ESR2ALDH1A1MAPK1CYP2A6 | |
| SCHEMBL21277258 | 0.84 | ALDH1A1 (0.45) | ESR2ALDH1A1MAPK1PPARG | |
| SCHEMBL6326863 | 0.83 | ESR2 (0.48) | ESR2ALDH1A1MAPK1CYP2A6CYP2B6 | |
| SCHEMBL14305807 | 0.83 | ALDH1A1 (0.50) | ESR2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002006187-A1 | METHOD FOR PREPARING A POLYAROMATIC COMPOUND | RHODIA CHIMIE (FR) | 2002-01-24 | — | — | WO | claimed |
| CN-117820191-B | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | FUDAN UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-119930416-A | 2-Bromofluorenone prepared by air oxidation bromination, and method and application thereof | 陕西煤业化工技术研究院有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| CN-118527068-A | Tubular reactor capable of continuously producing Grignard reagent | 吉林化工学院 | 2024-08-23 | — | — | CN | disclosed |
| CN-117820191-A | Diphenylamine compound and preparation method, application and pharmaceutical composition thereof | 复旦大学 | 2024-04-05 | — | — | CN | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230309369-A1 | Organic Light-Emitting Device | LG CHEM, LTD. (KR) | 2023-09-28 | — | — | US | disclosed |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | SRI INTERNATIONAL (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115960032-A | Aryloxy propanol amine beta-adrenaline receptor ligand with beta-arrestin biased agonistic activity and application thereof | 复旦大学 | 2023-04-14 | — | — | CN | disclosed |
| US-6350907-B1 | PEPTIDE ENZYME INHIBITORS | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
| WO-2002006187-A1 | METHOD FOR PREPARING A POLYAROMATIC COMPOUND | RHODIA CHIMIE (FR) | 2002-01-24 | — | — | WO | disclosed |
| CN-1284942-A | matrix metalloproteinase inhibitors | PFIZER LTD (US) | 2001-02-21 | — | — | CN | disclosed |
| EP-1047665-A1 | MATRIX METALLOPROTEASE INHIBITORS | Pfizer Limited (GB) | 2000-11-02 | — | — | EP | disclosed |
| EP-1036062-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | Pfizer Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| US-6090852-A | MATRIX METALLOPROTEASE INHIBITOR | PFIZER INC (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0931788-A2 | Metalloprotease inhibitors | Pfizer Limited (GB) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999035124-A1 | MATRIX METALLOPROTEASE INHIBITORS | PFIZER LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999029667-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE (MMP) INHIBITORS | PFIZER LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
| US-4029594-A | Novel liquid crystal compounds and electro-optic devices incorporating them | RCA CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | ESR2 799/4885ALDH1A1 177/4885MAPK1 1182/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | ESR2 188/4885ALDH1A1 1126/4885MAPK1 1092/4885 |
| US-20230174485-A1 | LIPOXYGENASE INHIBITORS | ALOX15B, ALOX12, ALOX15 | ESR2 1784/4885ALDH1A1 133/4885MAPK1 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.